Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Liabilities: 2015-2024

Historic Other Non-Current Liabilities for Voyager Therapeutics (VYGR) over the last 9 years, with Sep 2024 value amounting to $39.4 million.

  • Voyager Therapeutics' Other Non-Current Liabilities rose 108.09% to $39.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $39.4 million, marking a year-over-year increase of 108.09%. This contributed to the annual value of $18.1 million for FY2023, which is 15.03% down from last year.
  • As of Q3 2024, Voyager Therapeutics' Other Non-Current Liabilities stood at $39.4 million, which was down 4.46% from $41.2 million recorded in Q2 2024.
  • Voyager Therapeutics' Other Non-Current Liabilities' 5-year high stood at $44.4 million during Q4 2020, with a 5-year trough of $18.1 million in Q4 2023.
  • Its 3-year average for Other Non-Current Liabilities is $27.7 million, with a median of $22.0 million in 2022.
  • In the last 5 years, Voyager Therapeutics' Other Non-Current Liabilities tumbled by 46.30% in 2022 and then spiked by 109.51% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $44.4 million in 2020, then decreased by 10.81% to $39.6 million in 2021, then plummeted by 46.24% to $21.3 million in 2022, then declined by 15.03% to $18.1 million in 2023, then skyrocketed by 108.09% to $39.4 million in 2024.
  • Its last three reported values are $39.4 million in Q3 2024, $41.2 million for Q2 2024, and $43.0 million during Q1 2024.